Forest Labs to buy Aptalis from TPG for $2.9 bln

Drugmaker Forest Laboratories Inc, which averted a proxy fight with activist investor Carl Icahn last year, said on Wednesday it would buy specialty pharmaceutical maker Aptalis from private equity firm TPG Capital for $2.9 billion, sending its shares sharply higher, sister news service Reuters reported.